Hydroxychloroquine safety in Covid-19 vs non-Covid-19 patients: analysis of differences and potential interactions-Reference-Cited by-同舟云学术

Hydroxychloroquine safety in Covid-19 vs non-Covid-19 patients: analysis of differences and potential interactions

Published:2022-05-19 Issue:1 Volume:22 Page:71-79
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Sainz-Gil María¹²,Merino Kolly Nieves³,Velasco-González Verónica¹²⁴,Verde Rello Zoraida²⁵,Fernandez-Araque Ana M²⁶,Sanz Fadrique Rosario¹,Martín Arias Luis H¹²

Affiliation:

1. Centro de Estudios sobre la Seguridad de los Medicamentos (CESME). Departamento de Biología Celular, Histología, Farmacología y Genética. Facultad de Medicina. Universidad de Valladolid, Valladolid, Spain

2. Grupo de Investigación Reconocido “Pharmacogenetics, Cancer Genetics, Genetic Polymorphisms and Pharmacoepidemiology”, Universidad de Valladolid, Valladolid, Spain

3. Centro Andaluz de Farmacovigilancia. Dirección General de Salud Pública, Consejería de Salud y Familias, Junta de Andalucía. Avda, Sevillla, Spain

4. Departamento de Enfermería, Universidad de Valladolid, Valladolid, Spain

5. Departamento de Bioquímica, Biología Molecular y Fisiología, Universidad de Valladolid, Campus Universitario Duques de Soria, Soria, Spain

6. Departamento de Enfermería, Universidad de Valladolid, Campus Universitario Duques de Soria, Soria, Spain

Funder

‘Analysis of drug interactions in the treatment of COVID-19 patients’ and was supported by the Scientific Foundation of Caja Rural De Soria

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2022.2078303

Reference46 articles.

1. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

2. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

3. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

4. Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

5. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the impact of co-exposure timing on drug-drug interactions in signal detection through spontaneous reporting system databases: a scoping review;Expert Review of Clinical Pharmacology;2024-04-18

2. Inhalable chitosan-based hydrogel as a mucosal adjuvant for hydroxychloroquine in the treatment for SARS-CoV-2 infection in a hamster model;Journal of Microbiology, Immunology and Infection;2023-10

3. COVID-19 and its treatments: lights and shadows on testicular function;Endocrine;2022-10-19